Report an Adverse Reaction or Product Issue
Lamyra places the highest priority on the safety and quality of its products. In accordance with applicable pharmacovigilance regulations, Lamyra continuously monitors the safety of its products and evaluates reported adverse reactions and product-related issues. We comply with regulatory requirements across the CIS and MENA regions and follow international Good Pharmacovigilance Practice (GVP) standards. If you experience or become aware of an adverse reaction, a lack of effect, a product quality complaint, or any other safety-related issue associated with a Lamyra product, please report it using the form below.
You may also report safety information by email at: PVmena@lamyra.org
Lamyra processes personal data in accordance with applicable pharmacovigilance legislation, including Good Pharmacovigilance Practice (GVP), the General Data Protection Regulation (GDPR) where applicable, and relevant national laws in the CIS and MENA regions.
All information collected through this form or via email is used exclusively for pharmacovigilance purposes and, where required, for mandatory reporting to regulatory authorities in the relevant countries. Personal data are not shared with third parties unless required by law to protect public health and patient safety.
By submitting this report, you acknowledge that:
-
The information is provided voluntarily;
-
The information may be used to fulfill Lamyra’s pharmacovigilance and regulatory obligations;
-
Lamyra may contact you to request clarification or additional information related to this report.
